533 reports of this reaction
2.2% of all GANCICLOVIR SODIUM reports
#8 most reported adverse reaction
PANCYTOPENIA is the #8 most commonly reported adverse reaction for GANCICLOVIR SODIUM, manufactured by Fresenius Kabi USA, LLC. There are 533 FDA adverse event reports linking GANCICLOVIR SODIUM to PANCYTOPENIA. This represents approximately 2.2% of all 23,974 adverse event reports for this drug.
Patients taking GANCICLOVIR SODIUM who experience pancytopenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PANCYTOPENIA is a less commonly reported adverse event for GANCICLOVIR SODIUM, but still significant enough to appear in the safety profile.
In addition to pancytopenia, the following adverse reactions have been reported for GANCICLOVIR SODIUM:
The following drugs have also been linked to pancytopenia in FDA adverse event reports:
PANCYTOPENIA has been reported as an adverse event in 533 FDA reports for GANCICLOVIR SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
PANCYTOPENIA accounts for approximately 2.2% of all adverse event reports for GANCICLOVIR SODIUM, making it a notable side effect.
If you experience pancytopenia while taking GANCICLOVIR SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.